Alvotech (ALVO) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Alvotech (ALVO) over the past year, gaining 19.3% versus a loss of 34.7%. Denali Therapeutics is the larger company by market cap ($2.98 billion vs $2.02 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | DNLI |
|---|---|---|
| Share price | $5.67 | $18.67 |
| Market cap | $2.02B | $2.98B |
| 1-day change | -3.08% | -2.56% |
| YTD return | +10.53% | +13.08% |
| 1-year return | -34.68% | +19.30% |
| 5-year return | — | -59.02% |
| Forward P/E | 24.83 | — |
| EPS (TTM) | $-0.62 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $0 |
| Revenue growth (YoY) | +19.74% | — |
| Net income (latest FY) | $27.92M | $-512.54M |
| Gross margin | 59.82% | — |
| Operating margin | 13.34% | — |
| Net margin | 4.76% | — |
| 52-week high | $9.05 | $27.30 |
| 52-week low | $2.94 | $13.75 |
| Distance from 52-week high | -37.31% | -31.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +19.93% | +93.14% |
| Average volume | 1.05M | 1.62M |
| Shares outstanding | 356.82M | 159.85M |
| Employees | 1,279 | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed ALVO by 54.0 percentage points over the past year.
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
ALVO vs DNLI FAQ
Which is bigger, Alvotech or Denali Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.98B compared with $2.02B for Alvotech (ALVO).
Which stock has performed better over the past year, ALVO or DNLI?
DNLI returned +19.30% over the past 12 months, compared with -34.68% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.